MEMPHIS, Tenn., Oct. 20 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men’s Health Biotech Company, today announced that it will host a conference call and webcast to discuss the Company’s third quarter 2005 financial results on Thursday, November 3 at 10:00 a.m., Eastern Time. The call and webcast will follow the release of the third quarter 2005 financial results earlier that day.
To listen to the conference call, please dial: * 800-510-9834 from the United States and Canada or * 617-614-3669 (International) The access code for the call is 39485009. A playback of the call will be available from approximately 12:00 p.m., Eastern Time, on November 3 through November 17 and may be accessed by dialing: * 888-286-8010 from the United States and Canada or * 617-801-6888 (International), referencing reservation number 95133732.
Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the Company’s website at http://www.gtxinc.com.
About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men’s health. GTx’s lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx, headquartered in Memphis, Tenn., currently has four clinical programs. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: (1) a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy and (2) a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions. In its third clinical program, GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for the treatment of muscle wasting associated with acute conditions such as burns and evaluating the drug’s development for chronic conditions such as andropause. GTx plans to initiate its first Phase II clinical trial of ostarine in the fourth quarter of 2005. In its fourth clinical program, GTx and its collaborator, Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine, another one of GTx’s SARMs, for the treatment of cancer cachexia. GTx is working with Ortho Biotech to plan a Phase II clinical trial of andarine.
GTx, Inc.
CONTACT: McDavid Stilwell, GTx, Inc., Manager, Corporate Communicationsand Financial Analysis, +1-901-523-9700
Web site: http://www.gtxinc.com/
